Skip to main content

Table 3 Endoscopic findings and comparison between rebleeding and no-rebleeding group

From: Development and validation of a model to predict rebleeding within three days after endoscopic hemostasis for high-risk peptic ulcer bleeding

Characteristic Total Rebleeding Non-rebleeding P
N = 386 N = 48 N = 338
Ulcer location [No. (%)]     0.282
 Fundus 18 (4.7) 1 (2.1) 17 (5)  
 Body 63 (16.3) 7 (14.6) 56 (16.6)  
 Angulus 18 (4.7) 1 (2.1) 17 (5)  
 Antrum 41 (10.6) 4 (8.3) 37 (10.9)  
 Duodenum 193 (50) 32 (66.7) 161 (47.6)  
 Anastomotic site 53 (13.7) 3 (6.3) 50 (14.8)  
Ulcer size ≥ 2 cm [No. (%)] 35 (9.1) 7 (14.6) 28 (8.3) 0.249
Stigmata of hemorrhage [No. (%)]     0.001
 Forrest Ia 22 (5.7) 7 (14.6) 15 (4.4)  
 Forrest Ib 144 (37.3) 26 (54.2) 118 (34.9)  
 Forrest IIa 121 (31.1) 7 (14.6) 114 (33.7)  
 Forrest IIb 99 (25.6) 8 (16.7) 91 (29.6)  
Methods of endoscopic hemostasis [No. (%)]     0.453
 Injection therapy 224 (58) 30 (62.5) 194 (57.4)  
 Thermal coagulation 18 (4.7) 2 (4.2) 16 (4.7)  
 Mechanical therapy 60 (15.5) 4 (8.3) 56 (16.6)  
 Combination therapy 84 (21.8) 12 (25) 72 (21.3)